Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 106 results for magnetic

  1. Transcranial magnetic stimulation for chronic primary pain: What is the clinical and cost effectiveness of transcranial magnetic stimulation for managing chronic primary pain in people aged 16 years and over?

    Transcranial magnetic stimulation for chronic primary pain: What is the clinical and cost effectiveness of transcranial...

    Research recommendation
    Published
    6 August 2021

  2. Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)

    Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.

    HealthTech guidance
    Published
    5 October 2022
    View recommendations

    Sections for HTG642

  3. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

    NICE guideline
    Published
    7 April 2021
    View recommendations

    Sections for NG193

  4. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

    Clinical guideline
    Last updated
    26 April 2023
    View recommendations

    Sections for CG104

  5. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 January 2014
    View quality statements

    Sections for QS52

  6. NaviCam for diagnosing gastrointestinal tract conditions (MIB104)

    NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .

    Medtech innovation briefing
    Published
    11 May 2017

  7. Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA918)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.

    Technology appraisal guidance
    Published
    11 October 2023
    View recommendations

    Sections for TA918

  8. Evidence on the safety of magnetic resonance therapy for knee osteoarthritis shows no major safety concerns. Evidence on efficacy is inadequate in quality and quantity and shows no benefit over placebo. Therefore, this procedure should not be used unless it is part of a research study. Further research should be in the form of appropriately powered randomised  controlled trials comparing the procedure with placebo. It should report patient  selection and treatment protocols, including the number of sessions and  magnetic field strength.

    Recommendation ID IPG702/1 Question Evidence on the safety of magnetic resonance therapy for knee osteoarthritis shows no major safety...

    Research recommendation
    Published
    30 September 2021

  9. Advanced breast cancer: diagnosis and treatment (CG81)

    This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.

    Clinical guideline
    Last updated
    19 February 2025
    View recommendations

    Sections for CG81

  10. Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major safety concerns. However, evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.  Find out  what only in research means on the NICE website .

    ID IPG676 Question Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major safety...

    Research recommendation
    Published
    10 August 2020

  11. What are the long-term benefits and harms, and cost effectiveness of endoscopic ultrasound (EUS) compared with magnetic resonance cholangiopancreatography (MRCP) in adults with suspected common bile duct stones?

    harms, and cost effectiveness of endoscopic ultrasound (EUS) compared with magnetic resonance cholangiopancreatography (MRCP) in adults...

    Research recommendation
    Published
    9 June 2015

  12. Therapeutic percutaneous image-guided aspiration of spinal cysts (HTG143)

    Evidence-based recommendations on therapeutic percutaneous image-guided aspiration of spinal cord cysts. This involves using a needle to drain the cyst and remove pressure on the spinal cord or nerve roots.

    HealthTech guidance
    Last updated
    1 August 2007
    View recommendations

    Sections for HTG143

  13. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

    NICE guideline
    Published
    6 July 2016
    View recommendations

    Sections for NG49

  14. NICE encourages further research on transcranial magnetic stimulation (TMS) for treating and preventing migraine. Data should be collected for all patients not entered into controlled trials. Studies should describe clearly whether its use is for treatment or prevention. They should report details of patient selection and the dose and frequency of use. Outcome measures should include the number and severity of migraine episodes, and quality of life in both the short and long term. The development of any neurological disorders (such as epilepsy) in the short or longer term after starting treatment should be documented.

    IPG477/1 Question NICE encourages further research on transcranial magnetic stimulation (TMS) for treating and preventing migraine. Data...

    Research recommendation
    Published
    9 June 2015

  15. Evidence on the safety of transcranial magnetic stimulation for auditory hallucinations is adequate and raises no major safety concerns. However, evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. Find out  what only in research means on the NICE interventional procedures guidance page . Further research should be in the form of randomised controlled trials and should use well described treatment protocols. Studies should report details of patient selection including specific psychopathology, underlying disease and other treatments, the area of brain treated and the imaging used to target it, and long-term outcomes for at least 1 year.

    IPG680 Question Evidence on the safety of transcranial magnetic stimulation for auditory hallucinations is adequate and raises no major

    Research recommendation
    Published
    26 October 2020